. & #0 3 , ) - ,0 -/,0#0 & , . AND MEN WITHOUT SYMPTOMS MAY NOT BENElT FROM IMMEDIATE TREATMENT ESPECIALLY IF THEY ARE IN OTHERWISE POOR HEALTH #OMPARISONS BY !*## 3TAGE FOR 0ROSTATE #ANCER #ASES "ETWEEN .#$" .#$" 3TATE OF ,OUISIANA (OSPITALS /NLY 340( AND 2EFERRED TO !NOTHER 2ADIATION #ENTER AND 4HOSE 4REATED /NLY AT 340( -"0## 4REATMENT !*## 3TAGE !LL 3TAGES ) )) ))) )6 .#$" .#$" 34!4% /& ,/5)3)!.! N N 340( 2%&%22%$ 4/ ! 2!$)!4)/. #%.4%2 N < 340( 2%&%22%$ 4/ -"0## N < < !*## !MERICAN *OINT #OMMISSION ON #ANCER .#$" DATA REPORTED FROM (OSPITALS OF ALL TYPES .#$" DATA REPORTED FROM (OSPITALS OF ALL TYPES < NO COMPARISON DATA . & ., .' (. )'* ,#-)( -.*" ' * *,)-. . - -IXED 4.- 3TAGE 3TAGE ) 3TAGE )) 3TAGE ))) 3TAGE )6 !GE AT $IAGNOSIS -EAN AGE -EDIAN AGE 2ACE 7HITE !FRICAN !MERICAN (AWAIIAN 3URVIVAL /BSERVED 0ROSTATE #ANCER /UTCOMES 3TUDY ) 3URGERY "RACHYTHERAPY 2ADIATION %XTERNAL "EAM 2ADIATION N N 4OTAL #ASES .O 2ADIATION N N < < < < < -AY NOT EQUAL DUE TO ROUNDING %XCLUDES UNKNOWN AND NOT APPLICABLE STAGES < .O COMPARISON DATA -ANY FACTORS INmUENCE TREATMENT OPTIONS INCLUDING AGE STAGE OF THE CANCER THE PRESENCE OF OTHER CO EXISTING OR CHRONIC CONDITIONS AND PROGNOSTIC INDICATORS SUCH AS 03! LEVELS AND THE TOTAL 'LEASON SCORE .UMEROUS TREATMENT MODALITIES ARE AVAILABLE THAT ALLOW FOR INDIVIDUALIZED TREATMENT PLANNING 3URGERY AND EXTERNAL BEAM RADIATION OR BRACHYTHERAPY IMPLANTATION OF RADIOACTIVE SEED IMPLANTS AT THE TUMOR SITE MAY BE USED TO TREAT EARLY STAGE DISEASE #OMBINATIONS OF CHEMOTHERAPY HORMONE THERAPY AND OR RADIATION THERAPY MAY BE USED TO TREAT ADVANCED DISEASE OR AS ADJUVANT TREATMENT FOR EARLY STAGE DISEASE h7ATCHFUL WAITING v OR OBSERVATION MAY BE APPROPRIATE FOR OLDER MEN WHO HAVE LESS AGGRESSIVE TUMORS OR LIMITED LIFE EXPECTANCY 0ROSTATE CANCER TREATMENT GUIDELINES ESTABLISHED BY THE .ATIONAL #OMPREHENSIVE #ANCER .ETWORK .##. ARE AVAILABLE FOR PATIENTS AND CLINICIANS ON THE !#3 WEBSITE WWW CANCER ORG AND THE .##. WEBSITE WWW NCCN ORG 4HE #ANCER #OMMITTEE COMPARED PATTERNS OF TREATMENT AND OUTCOMES SURVIVAL OF PATIENTS DIAGNOSED AND TREATED WITH PROSTATE CANCER AT 340( AND -"0## WITH THE .ATIONAL #ANCER $ATA "ASE .#$" "ENCHMARK 2EPORT DURING THE REPORTING PERIOD 4ABLE PROVIDES A STATISTICAL OVERVIEW OF COMPARISONS WITH NO VARIATIONS OF SIGNIlCANCE NOTED IN AGE PRESENTING STAGE OR HISTOLOGIES ! HIGHER PERCENTAGE OF WHITE MALES AND MANAGED CARE PATIENTS WAS NOTED WHEN COMPARED TO .#$" DATA 4REATMENT DISTRIBUTION PATTERNS WERE QUITE SIMILAR TO NATIONAL DATA WITH THE EXCEPTION OF BRACHYTHERAPY WHERE THERE WAS A NOTICABLE INCREASE IN PATIENTS TREATED AT 340( -"0## WITH THIS TREATMENT OPTION 4HE OBSERVED lVE YEAR SURVIVAL RATE OF PATIENTS TREATED AT 340( AND REFERRED FOR RADIATION WERE COMPARED TO PATIENTS TREATED AT 340( AND REFERRED TO -"0## FOR RADIATION TREATMENT /VERALL SURVIVAL RATES 4ABLE FOR ALL STAGES FOR PATIENTS TREATED AT 340( WAS PERCENT WHICH WAS COMPARABLE TO NATIONAL AND STATE DATA (OWEVER PATIENTS RECEIVING TREATMENT AT 340( AND RADIATION AT -"0## WAS PERCENT WHICH WAS HIGHER THAN NATIONAL OR STATE DATA 4HIS INCREASE IN SURVIVAL COULD BE ATTRIBUTED TO THE INTRODUCTION AND UTILIZATION OF BRACHYTHERAPY AS A TREATMENT FOR PROSTATE CANCER IN AND THE FACT THAT THIS OPTION IS MOST COMMONLY UTILIZED FOR EARLY STAGE DISEASE 4HE #OMMITTEE ALSO WANTED TO COMPARE SURVIVAL IN PROSTATE CANCER CASES TREATED WITH NO RADIATION SURGERY WITH EXTERNAL BEAM RADIATION OR BRACHYTHERAPY WITH OR WITHOUT EXTERNAL BEAM RADIATION TO DETERMINE DIFFERENCES IN TREATMENT AND SURVIVAL 4ABLE ! TOTAL OF CASES DIAGNOSED BETWEEN WERE INCLUDED /F THOSE CASES RECEIVED SURGERY WITH EXTERNAL BEAM RADIATION PATIENTS RECEIVED BRACHYTHERAPY WITH OR WITHOUT EXTERNAL BEAM RADIATION AND PATIENTS DID NOT REQUIRE ANY TYPE OF RADIATION TREATMENT 4HE MAJORITY CONTINUED ON NEXT PAGE -"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24